Proteomic identification of angiomotin by ProteomeLab PF-2D and correlation with clinical outcome in human clear cell renal cell carcinoma

International Journal of Oncology

Volumn 42, Issue 6, 2013, Pages 2078-2086

  Yang, Jin ^a   Liu, Peijun ^a   Tian, Meijuan ^a   Li, Yuyao ^a   Chen, Wei ^a   Li, Xu ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Angiomotin; Clear cell renal cell carcinoma; HK 2; PF 2D; Proteomics; RLC 310

Indexed keywords

ANGIOMOTIN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL FRACTIONATION; CHROMATOFOCUSING; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; FROZEN SECTION; HUMAN; HUMAN TISSUE; HYDROPHOBICITY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; TUMOR CELL; WESTERN BLOTTING;

CARCINOMA, RENAL CELL; CELL LINE; CELL LINE, TUMOR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; KIDNEY NEOPLASMS; LIQUID-LIQUID EXTRACTION; MEMBRANE PROTEINS; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEOMICS; REFERENCE VALUES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SURVIVAL RATE; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 84876521614     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1889     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Drucker BJ: Renal cell carcinoma: current status and future prospects. Cancer Treat Rev 31: 536-545, 2005. (Pubitemid 41614811)
3. Fisher RI, Rosenberg SA and Fyfe G: Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6 (Suppl 1): S55-S57, 2000.
4. Messing EM, Manola J, Wilding G, et al: Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21: 1214-1222, 2003. (Pubitemid 46606396)
5. Gonzalez LJ, Espinosa E and Garcia CI, et al: Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second-or subsequent-line therapy with a different mechanism of action. Cancer Metastasis Rev 31 (Suppl 1): S11-S17, 2012.
6. Patard JJ, Pouessel D, Bensalah K and Culine S: Targeted therapy in renal cell carcinoma. World J Urol 26: 135-140, 2008.
7. Rathmell WK and Chen S: VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Rev Anticancer Ther 8: 63-73, 2008.
8. Audenet F, Yates DR, Cancel-Tassin G, Cussenot O and Roupret M: Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. BJU Int 109: 1864-1870, 2012.
9. Cho IC and Chung J: Current status of targeted therapy for advanced renal cell carcinoma. Korean J Urol 53: 217-228, 2012.
10. Simpson RJ and Dorow DS: Cancer proteomics: from signaling networks to tumor markers. Trends Biotechnol 19: S40-S48, 2001.
11. Banks RE, Craven RA, Harnden P, Madaan S, Joyce A and Selby PJ: Key clinical issues in renal cancer: a challenge for proteomics. World J Urol 25: 537-556, 2007.
12. Petricoin EF, Zoon KC, Kohn EC, Barrett JC and Liotta LA: Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 1: 683-695, 2002. (Pubitemid 37361543)
13. Arsanious A, Bjarnason GA and Yousef GM: From bench to bedside: current and future applications of molecular profling in renal cell carcinoma. Mol Cancer 8: 20, 2009.
14. Nogueira M and Kim HL: Molecular markers for predicting prognosis of renal cell carcinoma. Urol Oncol 26: 113-124, 2008. (Pubitemid 351288566)
15. Wood SL, Rogers M, Cairns DA, et al: Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br J Cancer 103: 101-111, 2010.
16. Yang J, Li A, Yang Y and Li X: Identifcation of cyclophilin A as a potential prognostic factor for clear-cell renal cell carcinoma by comparative proteomic analysis. Cancer Biol Ther 11: 535-546, 2011.
17. Chen C, Ridzon DA, Broomer AJ, et al: Real-time quantifcation of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179, 2005.
18. Chang J T, Chen IH, Liao CT, et al: A reverse transcription comparative real-time PCR method for quantitative detection of angiogenic growth factors in head and neck cancer patients. Clin Biochem 35: 591-596, 2002. (Pubitemid 36009325)
19. Kikuno R, Nagase T, Ishikawa K, et al: Prediction of the coding sequences of unidentified human genes. XIV. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res 6: 197-205, 1999.
20. Troyanovsky B, Levchenko T, Mansson G, Matvijenko O and Holmgren L: Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 152: 1247-1254, 2001. (Pubitemid 34280181)
21. Levchenko T, Bratt A, Arbiser JL and Holmgren L: Angiomotin expression promotes hemangioendothelioma invasion. Oncogene 23: 1469-1473, 2004. (Pubitemid 38406842)
22. Jiang WG, Watkins G, Douglas-Jones A, Holmgren L and Mansel RE: Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancer. BMC Cancer 6: 16, 2006.
23. Holmgren L, Ambrosino E, Birot O, et al: A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci USA 103: 9208-9213, 2006. (Pubitemid 43902557)
24. Levchenko T, Veitonmaki N, Lundkvist A, et al: Therapeutic antibodies targeting angiomotin inhibit angiogenesis in vivo. FA SEB J 22: 880-889, 2008. (Pubitemid 351348139)
25. Arigoni M, Barutello G, Lanzardo S, et al: A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors. Angiogenesis 15: 305-316, 2012.
26. Wells CD, Fawcett J P, Traweger A, et al: A Rich1/Amot complex regulates the Cdc42 GTPase and apical-polarity proteins in epithelial cells. Cell 125: 535-548, 2006.
27. Aase K, Ernkvist M, Ebarasi L, et al: Angiomotin regulates endothelial cell migration during embryonic angiogenesis. Genes Dev 21: 2055-2068, 2007. (Pubitemid 47267291)
28. Yi C, Troutman S, Fera D, et al: A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell 19: 527-540, 2011.
29. Zhao B, Li L, Lu Q, et al: Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev 25: 51-63, 2011.
30. Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C and Hong W: Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J Biol Chem 286: 7018-7026, 2011.
31. Rini BI: VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices. Curr Oncol Rep 8: 85-89, 2006.
32. Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature 438: 967-974, 2005. (Pubitemid 43093963)
33. Hu Y, Liu J and Huang H: Recent agents targeting HIF-1alpha for cancer therapy. J Cell Biochem 114: 498-509, 2013.
34. Rathmell WK, Wright TM and Rini BI: Molecularly targeted therapy in renal cell carcinoma. Expert Rev Anticancer Ther 5: 1031-1040, 2005. (Pubitemid 43033793)